DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a new analysis of MRI data from the Phase 3 clinical trial of UPLIZNA showing a reduction in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback